I think we agree there will be growth and new products and services. With new employees being brought in it may take some time to get to the point that is all contributing to the bottom line. Let me correct something and say they are pointed in the right direction, just need some time to get there. With earnings in a couple weeks I believe we will hear about increased expense related to hiring, training and product development. What impact that has on current earnings or on the next couple Qtrs is hard to judge. I will be listening to hear the plan they have laid out and any timelines.
They have a long way to go with getting this pointed in the right direction, which imo, they eventually will. The annual report lays out a fairly standard report with all the pitfalls listed which is typical for an Annual report and no surprises. It sounds as if the Board and Shiji are on the sidelines calling the plays and letting Senior Management at eFuture execute the plan. Someday (we do not know the timetable) it will all come together and the new business plan will be made known. There will be new products and services merged perhaps with Shiji's existing businesses. Until then it may be a good opportunity to add or enter a position depending on your personal situation.
Not sure why you think that. Just means eFuture's technology will not only be used by Shiji but most likely eventually Alibaba and the geographic regions are expanding. Very positive statements by Mr. King, especially when referring to "Profitable growth for shareholders".
It will be interesting to see how they will use/incorporate Efuture's business with Shiji's and what the results will be. Tremendous value creation here and Shiji with their resouces did not take this position as an experiment, they know exactly what they are doing and where this is headed, imo.
Up 50% in a month on little news, low volume but a lot of pump from Zack's, leads me to believe the shorts are taking a hard look at this one. Yes, be careful!
I would encourage you to contact the Company Secretary and pose the question. If enough shareholders contact them, maybe they would clarify the situation.
The meeting to vote new Directors in will be on February 29th. Until that happens I do not think we get much clarity or news.
If you go to the Medigen Biotechology website, based in Taiwan, you will read a glowing summary of PI-88 and the Patron trial, although there is no update on their website. Medigen talks about owning Worldwide commercialization rights for PI-88 but does not mention Progen or TBG Diagnostics at all. I could not find any mention of PI-88 now in the mention of TBG Diagnostics limited. If PI-88 was valued at only 5 million, then why is it mentioned as a major candidate for possible approval for Liver Cancer on Medigen's website? There are a lot of questions to be answered by both Companies.